Biotech Startups

Eigen develops co-therapies that modulate cancer cell target expression to improve the effectiveness of targeted treatments such as antibody-drug conjugates and radioligand therapies. It uses a discovery platform combining machine learning, robotic automation, and high-throughput combinatorial screening to design combination therapies addressing tumor heterogeneity.

3 investors

Ekso Bionics develops wearable exoskeleton robotics used to help people with paralysis stand and walk, to augment worker physical capabilities, and to support rehabilitation and R&D. It serves medical/rehabilitation and industrial markets in the healthcare robotics and medical device category.

3 investors

Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.

3 investors

Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.

3 investors

Elucid develops artificial intelligence technology that analyzes CT images to identify hidden features of cardiovascular risk and guide personalized treatment of coronary artery disease. The platform enables physicians to create detailed disease maps and deliver personalized care based on individual patient anatomy.

3 investors

Clinical-stage specialty pharma developing a combination drug to treat a range of addictions, licensed from LSU Health Sciences Center.

3 investors

Empirico is a San Diego-based clinical-stage biotech that uses human genetics data and computational methods to discover disease targets and develop siRNA and antibody therapeutics.

3 investors

Enable Medicine builds an integrated biological data platform that organizes and links clinical, spatial, cellular, and molecular data from patients and studies into a unified index to accelerate therapeutic discovery and diagnostics for researchers.

3 investors

ENB Therapeutics develops small molecules targeting the endothelin B receptor (ETBR) in the tumor microenvironment to treat drug-resistant cancers by restoring immune cell infiltration and promoting tertiary lymphoid organ formation. Its preclinical therapies target cancers including melanoma, glioblastoma, squamous cell carcinoma, bladder cancer, and ovarian cancer.

3 investors

Endometrics is a molecular diagnostics company developing non-invasive tests for women's health that use menstrual blood as an organ-proximal liquid biopsy, with an initial focus on endometriosis. It combines tissue-derived biomarker discovery, bioinformatics, and at-home sample collection to enable molecular diagnostics for gynecologic diseases.

3 investors

Endra provides an AI-powered platform for MEP (mechanical, electrical, plumbing) and fire protection engineers to automate design, documentation, and compliance workflows within Autodesk Revit. The platform generates 2D/3D models, shop drawings, calculations, and compliance documentation for building systems across EU, UK, and US markets.

3 investors

Enedra analyzes tumor evolution patterns by decoding convergent genomic signatures from cancer genomic data. The company uses its CASPAROV platform to identify conserved genetic patterns across tumor populations and cancer models.

3 investors

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

3 investors

Engine Bio presents itself as a company working on new cancer medicines.

3 investors

EnsiliTech develops ensilication technology, a silica-based method to stabilise vaccines and biopharmaceuticals so they can be stored and transported without refrigeration. The company serves the pharmaceutical and biotech industry and originated from research at the University of Bath.

3 investors

Entac Medical develops wearable devices that apply predictive analytics and AI to biological acoustic signals to predict patient adverse events, aiming to improve patient outcomes and reduce hospital readmissions and cost of care. It serves the healthcare sector as a digital health company.

3 investors

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD. Its research targets the underlying mechanisms of mucus congestion in the lungs to reduce lung infections and improve patient quality of life.

3 investors

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

3 investors

Enumera Molecular develops technology and a platform for simplified, lower-cost workflows that enable liquid biopsy and high-dimensional omics assays for laboratories. It targets clinical labs performing molecular diagnostics.

3 investors

Develops novel ocular therapies.

3 investors

Enyo Pharma is a biotechnology company focused on drug development in the life sciences and therapeutics field. This page lists the venture capital and institutional firms that back the company.

3 investors

Ephemeral develops biodegradable tattoo ink designed to fade over time, offering a non-permanent alternative to traditional tattoos without laser removal. Founded by NYU PhD researchers, the company sells its black fade-away ink through partner tattoo artists and operates a studio in Brooklyn, New York.

3 investors

Epigenic Therapeutics develops gene regulation-based biotherapeutics using its EPIREG platform, which applies AI algorithms to design CRISPR-Cas components that regulate target gene expression without altering the DNA sequence. Combined with a lipid nanoparticle delivery system, the technology targets metabolic, cardiovascular, viral hepatitis, ocular, oncology and rare diseases.

3 investors

Epimab Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of bispecific antibodies using proprietary technology platforms including FIT-Ig® and MAT-Fab. The company is advancing a pipeline of novel candidates targeting unmet clinical needs, with a focus on oncology applications.

3 investors